Patents by Inventor David Edmund Bays
David Edmund Bays has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6677316Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: GrantFiled: August 13, 2002Date of Patent: January 13, 2004Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6610665Abstract: There are disclosed according to the invention, compounds of formula (I) wherein R1, R2 and R3 are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.Type: GrantFiled: August 29, 2000Date of Patent: August 26, 2003Assignee: Smithkline Beecham CorporationInventors: David Edmund Bays, Chuen Chan, Caroline Mary Cook, Brian Cox, Richard Peter Charles Cousins, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Stephen Swanson
-
Publication number: 20030096788Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: ApplicationFiled: August 13, 2002Publication date: May 22, 2003Applicant: Glaxo Wellcome Inc.Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6492348Abstract: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.Type: GrantFiled: March 6, 2001Date of Patent: December 10, 2002Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 5719185Abstract: The present invention relates to the use of GABA agonists having an agonist action at GABA.sub.B receptors in the treatment of emesis.Type: GrantFiled: October 23, 1995Date of Patent: February 17, 1998Assignee: Glaxo Group LimitedInventors: Charanjit Bountra, David Edmund Bays
-
Patent number: 4034075Abstract: Compounds of the general formula (I): ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 may be the same or different and each represents a hydrogen atom, an alkyl group, a nitro group, a halogen atom or a group of the formula --NR.sub.4 R.sub.5 or --OR.sub.4 ; in which the groups R.sub.4 and R.sub.5 may be the same or different and each represent a hydrogen atom, or an alkyl, alkenyl or cycloalkyl group (which alkyl group may optionally be substituted by alkoxy, hydroxy, amino, alkylamino, dialkylamino or aryl groups) or R.sub.4 and R.sub.5 together with the nitrogen atom form a heterocyclic ring which may optionally contain additional hetero atoms, e.g. morpholino or piperazinyl; and R.sub.6 represents a hydrogen atom or an alkyl group.These compounds have biological activity, particularly in inhibiting the release of spasmogenic substances arising as a consequence of antigen-antibody reactions.Type: GrantFiled: August 15, 1975Date of Patent: July 5, 1977Assignee: Allen & Hanburys LimitedInventors: David Edmund Bays, Mervyn Evan Peel, David Martin Waters, Gwynn Pennant Ellis
-
Patent number: 4028404Abstract: Novel phenylacetic derivatives are provided of the general formula ##STR1## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein, and pharmaceutically acceptable salts thereof. These have anti-inflammatory or analgetic activity. The invention also provides a process for the production of these compounds from a ketone of the structure: ##STR2## It also provides pharmaceutical compositions including phenylacetic derivatives.Type: GrantFiled: April 26, 1974Date of Patent: June 7, 1977Assignee: Allen & Hanburys LimitedInventors: David Edmund Bays, Roy Vivian Foster
-
Patent number: 4024255Abstract: Compounds of the general formulae I and II and pharmaceutically acceptable salts thereof: ##STR1## in which: R.sub.1 represents a hydrogen atom, a halogen atom, an alkenyl or alkyl group; or a group OR.sub.3 or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 which may be the same or different and may represent a hydrogen atom, or an alkenyl group, or an alkyl group which alkyl group may optionally be substituted by one or more hydroxy, alkoxy, acyloxy, aryl, amino, alkylamino, dialkylamino, diaralkylamino or alkylaralkylamino groups; or R.sub.3 and R.sub.4 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring that may optionally contain other hetero atoms.R.sub.2 has the same meanings as R.sub.3.The compounds have utility for the treatment of conditions in which combination of an antigen with a reaginic antibody is primarily responsible.Type: GrantFiled: September 25, 1975Date of Patent: May 17, 1977Assignee: Allen & Hanburys LimitedInventors: Gwynn Pennant Ellis, Ian Collins, David Martin Waters, David Edmund Bays
-
Patent number: 3943141Abstract: Compounds of the general formulae I and II and pharmaceutically acceptable salts thereof: ##SPC1##In which:R.sub.1 represents a hydrogen atom, a halogen atom, an alkenyl or alkyl group; or a group OR.sub.3 or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 which may be the same or different and may represent a hydrogen atom, or an alkenyl group, or an alkyl group which alkyl group may optionally be substituted by one or more hydroxy, alkoxy, acyloxy, aryl, amino, alkylamino, dialkylamino, diaralkylamino or alkylaralkylamino groups; or R.sub.3 and R.sub.4 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring that may optionally contain other hetero atoms.R.sub.2 has the same meanings as R.sub.3.The compounds have utility for the treatment of conditions in which combination of an antigen with a reaginic antibody is primarily responsible.Type: GrantFiled: March 27, 1974Date of Patent: March 9, 1976Assignee: Allen & Hanburys LimitedInventors: Gwynn Pennant Ellis, Ian Collins, David Martin Waters, David Edmund Bays
-
Patent number: 3932416Abstract: Compounds of the general formula (I): ##SPC1##in which R.sub.1, R.sub.2 and R.sub.3 may be the same or different and each represents a hdyrogen atom, an alkyl group, a nitro group, a halogen atom or a group of the formula --NR.sub.4 R.sub.5 or --OR.sub.4 ; in which the groups R.sub.4 and R.sub.5 may be the same or different and each represent a hydrogen atom, or an alkyl, alkenyl or cycloalkyl group (which alkyl group may optionally be substituted by alkoxy, hydroxy, amino, alkylamino, dialkylamino or aryl groups) or R.sub.4 and R.sub.5 together with the nitrogen atom form a heterocyclic ring which may optionally contain additional hetero atoms, e.g. morpholino or piperazinyl; and R.sub.6 represents a hydrogen atom or an alkyl group.These compounds have biological activity, particularly in inhibiting the release of spasmogenic substances arising as a consequence of antigen-antibody reactions.Type: GrantFiled: June 21, 1973Date of Patent: January 13, 1976Assignee: Allen & Hanburys LimitedInventors: David Edmund Bays, Mervyn Evan Peel, David Martin Waters, Gwynn Pennant Ellis